Evidence map›Paper›PMID 25803874›Full record

ArticlePloS one2015

Ectopic expression of a Neospora caninum Kazal type inhibitor triggers developmental defects in Toxoplasma and Plasmodium.

Zoi Tampaki, Ramadhan S Mwakubambanya, Evi Goulielmaki, Sofia Kaforou, Kami Kim, Andrew P Waters, Vern B Carruthers, Inga Siden-Kiamos, Thanasis G Loukeris, Konstantinos Koussis

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Zoi TampakiInstitute of Molecular Biology and Biotechnology, Foundation for Research and Technology-Hellas, Heraklion, Greece; Department of Biology, University of Crete, Heraklion, Greece.
Ramadhan S MwakubambanyaInstitute of Molecular Biology and Biotechnology, Foundation for Research and Technology-Hellas, Heraklion, Greece; Department of Biology, University of Crete, Heraklion, Greece.
Evi GoulielmakiInstitute of Molecular Biology and Biotechnology, Foundation for Research and Technology-Hellas, Heraklion, Greece; Department of Biology, University of Crete, Heraklion, Greece.
Sofia KaforouInstitute of Molecular Biology and Biotechnology, Foundation for Research and Technology-Hellas, Heraklion, Greece.
Kami KimDepartment of Medicine, Albert Einstein College of Medicine, Bronx, United States of America.
Andrew P WatersFaculty of Biomedical & Life Sciences, Glasgow Biomedical Research Centre, University of Glasgow, Glasgow, Scotland, United Kingdom.
Vern B CarruthersDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, United States of America.
Inga Siden-KiamosInstitute of Molecular Biology and Biotechnology, Foundation for Research and Technology-Hellas, Heraklion, Greece.
Thanasis G LoukerisInstitute of Molecular Biology and Biotechnology, Foundation for Research and Technology-Hellas, Heraklion, Greece.
Konstantinos KoussisInstitute of Molecular Biology and Biotechnology, Foundation for Research and Technology-Hellas, Heraklion, Greece.
Foundation for Research and Technology Hellas · GRAlbert Einstein College of Medicine · USUniversity of Crete · GRUniversity of Glasgow · GBUniversity of Michigan–Ann Arbor · US

Funding

Wellcome Trust 083811Wellcome Trust 104111
6 · The paper itself

Abstract

Regulated proteolysis is known to control a variety of vital processes in apicomplexan parasites including invasion and egress of host cells. Serine proteases have been proposed as targets for drug development based upon inhibitor studies that show parasite attenuation and transmission blockage. Genetic studies suggest that serine proteases, such as subtilisin and rhomboid proteases, are essential but functional studies have proved challenging as active proteases are difficult to express. Proteinaceous Protease Inhibitors (PPIs) provide an alternative way to address the role of serine proteases in apicomplexan biology. To validate such an approach, a Neospora caninum Kazal inhibitor (NcPI-S) was expressed ectopically in two apicomplexan species, Toxoplasma gondii tachyzoites and Plasmodium berghei ookinetes, with the aim to disrupt proteolytic processes taking place within the secretory pathway. NcPI-S negatively affected proliferation of Toxoplasma tachyzoites, while it had no effect on invasion and egress. Expression of the inhibitor in P. berghei zygotes blocked their development into mature and invasive ookinetes. Moreover, ultra-structural studies indicated that expression of NcPI-S interfered with normal formation of micronemes, which was also confirmed by the lack of expression of the micronemal protein SOAP in these parasites. Our results suggest that NcPI-S could be a useful tool to investigate the function of proteases in processes fundamental for parasite survival, contributing to the effort to identify targets for parasite attenuation and transmission blockage.

Indexed as

Cloning, MolecularDNA PrimersDrug Delivery SystemsDrug DiscoveryEctopic Gene ExpressionFluorescent Antibody Technique, IndirectImmunoblottingMicroscopy, Electron, TransmissionNeosporaPlasmidsPlasmodium bergheiProteolysisSerine Proteinase InhibitorsToxoplasmaTransfectionDNA PrimersSerine Proteinase Inhibitors

Identifiers

PMID25803874
PMCPMC4372514
OpenAlexW1985805032

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.